Sentinel Lymph Node Biopsy Without Systematic Pelvic Lymphadenectomy is Safe, Effective for Patients With Early-Stage Cervical Cancer
Featuring David Cibula, MD, PhD
At the Society of Gynecological Oncology (SGO) 2024 Annual Meeting, David Cibula, MD, PhD, General University Hospital, Prague, Czech Republic, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial. Results identified sentinel lymph node biopsy plus pathologic ultrastaging as a safe and effective method of detecting lymph node metastases among patients with early-stage cervical cancer.
Source:
Marnitz S, Klat J, Jarkovsky J, et al. Survival of patients with early-stage cervical cancer after SLN biopsy without systematic pelvic lymphadenectomy: Primary endpoint outcome of the SENTIX prospective, single-arm, international trial (CEEGOG CX-01; ENGOT-CX2). Presented at the SGO 2024 Annual Meeting; March 16-18, 2024; San Diego, California